235 related articles for article (PubMed ID: 38139458)
1. Constructed Risk Prognosis Model Associated with Disulfidptosis lncRNAs in HCC.
Jia X; Wang Y; Yang Y; Fu Y; Liu Y
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139458
[TBL] [Abstract][Full Text] [Related]
2. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
[TBL] [Abstract][Full Text] [Related]
3. A novel disulfidptosis-related lncRNA signature for predicting prognosis and potential targeted therapy in hepatocellular carcinoma.
Zhang H; Wang J; Yang M
Medicine (Baltimore); 2024 Jan; 103(4):e36513. PubMed ID: 38277541
[TBL] [Abstract][Full Text] [Related]
4. Disulfidptosis-Associated lncRNAs are Potential Biomarkers for Predicting Immune Response and Prognosis Within Individuals Diagnosed with Hepatocellular Carcinoma.
Wei Q; Hou YC; Mao FF; Feng JK; Wang X; Cheng SQ
Hepat Med; 2023; 15():249-264. PubMed ID: 38162389
[TBL] [Abstract][Full Text] [Related]
5. A novel disulfidptosis-related lncRNAs signature for predicting survival and immune response in hepatocellular carcinoma.
Guo Z; Xie Y; Zhang L; Liu S; Jiang W
Aging (Albany NY); 2024 Jan; 16(1):267-284. PubMed ID: 38180745
[TBL] [Abstract][Full Text] [Related]
6. Disulfidptosis-related lncRNAs signature predicting prognosis and immunotherapy effect in lung adenocarcinoma.
Hong S; Zhang Y; Wang D; Wang H; Zhang H; Jiang J; Chen L
Aging (Albany NY); 2024 Jun; 16(11):9972-9989. PubMed ID: 38862217
[TBL] [Abstract][Full Text] [Related]
7. Machine learning-based disulfidptosis-related lncRNA signature predicts prognosis, immune infiltration and drug sensitivity in hepatocellular carcinoma.
Pu L; Sun Y; Pu C; Zhang X; Wang D; Liu X; Guo P; Wang B; Xue L; Sun P
Sci Rep; 2024 Feb; 14(1):4354. PubMed ID: 38388539
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Novel Eight-lncRNA Prognostic Signature for HBV-HCC and Analysis of Their Functions Based on Coexpression and ceRNA Networks.
Zhao X; Bai Z; Li C; Sheng C; Li H
Biomed Res Int; 2020; 2020():8765461. PubMed ID: 32382578
[TBL] [Abstract][Full Text] [Related]
9. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
10. Identification of long noncoding RNAs biomarkers in patients with hepatitis B virus-associated hepatocellular carcinoma.
Mou Y; Wang D; Xing R; Nie H; Mou Y; Zhang Y; Zhou X
Cancer Biomark; 2018; 23(1):95-106. PubMed ID: 29991128
[TBL] [Abstract][Full Text] [Related]
11. A prognostic signature based on the expression profile of the ferroptosis-related long non-coding RNAs in hepatocellular carcinoma.
Lin X; Yang S
Adv Clin Exp Med; 2022 Oct; 31(10):1099-1109. PubMed ID: 35581934
[TBL] [Abstract][Full Text] [Related]
12. A novel seven-lncRNA signature for prognosis prediction in hepatocellular carcinoma.
Yan J; Zhou C; Guo K; Li Q; Wang Z
J Cell Biochem; 2019 Jan; 120(1):213-223. PubMed ID: 30206981
[TBL] [Abstract][Full Text] [Related]
13. Prognostic effect of a novel long noncoding RNA signature and comparison with clinical staging systems for patients with hepatitis B virus-related hepatocellular carcinoma after hepatectomy.
Wu H; Liu TT; Feng YM; Xie XY; Su XN; Qi JN; Zhu Q; Qin CY
J Dig Dis; 2020 Nov; 21(11):650-663. PubMed ID: 32959529
[TBL] [Abstract][Full Text] [Related]
14. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
16. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.
Zhao J; Luo Z; Fu R; Zhou J; Chen S; Wang J; Chen D; Xie X
Eur J Med Res; 2023 Dec; 28(1):571. PubMed ID: 38057871
[TBL] [Abstract][Full Text] [Related]
17. Disulfidptosis classification of hepatocellular carcinoma reveals correlation with clinical prognosis and immune profile.
Wang T; Guo K; Zhang D; Wang H; Yin J; Cui H; Wu W
Int Immunopharmacol; 2023 Jul; 120():110368. PubMed ID: 37247499
[TBL] [Abstract][Full Text] [Related]
18. A disulfidptosis-related lncRNAs signature in hepatocellular carcinoma: prognostic prediction, tumor immune microenvironment and drug susceptibility.
Liu Y; Meng J; Ruan X; Wei F; Zhang F; Qin X
Sci Rep; 2024 Jan; 14(1):746. PubMed ID: 38185671
[TBL] [Abstract][Full Text] [Related]
19. Integrated Bioinformatics and Experimental Validation to Identify a Disulfidptosis-Related lncRNA Model for Prognostic Prediction in Papillary Renal Cell Carcinoma.
Zhu Y; Jin X; Liu J
Comb Chem High Throughput Screen; 2024 Apr; ():. PubMed ID: 38639274
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma.
He H; Wang Y; Ye P; Yi D; Cheng Y; Tang H; Zhu Z; Wang X; Jin S
J Exp Clin Cancer Res; 2020 Aug; 39(1):159. PubMed ID: 32795316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
